CN105163745B - 从外周血中产生肿瘤反应性t细胞富集群的方法 - Google Patents

从外周血中产生肿瘤反应性t细胞富集群的方法 Download PDF

Info

Publication number
CN105163745B
CN105163745B CN201380075806.0A CN201380075806A CN105163745B CN 105163745 B CN105163745 B CN 105163745B CN 201380075806 A CN201380075806 A CN 201380075806A CN 105163745 B CN105163745 B CN 105163745B
Authority
CN
China
Prior art keywords
cells
tumor
reactive
cell
enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380075806.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105163745A (zh
Inventor
阿莱娜·格罗斯
史蒂文·A·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to CN202010410564.8A priority Critical patent/CN111643524B/zh
Publication of CN105163745A publication Critical patent/CN105163745A/zh
Application granted granted Critical
Publication of CN105163745B publication Critical patent/CN105163745B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ecology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
CN201380075806.0A 2013-03-01 2013-04-30 从外周血中产生肿瘤反应性t细胞富集群的方法 Active CN105163745B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010410564.8A CN111643524B (zh) 2013-03-01 2013-04-30 从外周血中产生肿瘤反应性t细胞富集群的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771251P 2013-03-01 2013-03-01
US61/771,251 2013-03-01
PCT/US2013/038813 WO2014133568A1 (en) 2013-03-01 2013-04-30 Methods of producing enriched populations of tumor reactive t cells from peripheral blood

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010410564.8A Division CN111643524B (zh) 2013-03-01 2013-04-30 从外周血中产生肿瘤反应性t细胞富集群的方法

Publications (2)

Publication Number Publication Date
CN105163745A CN105163745A (zh) 2015-12-16
CN105163745B true CN105163745B (zh) 2020-06-12

Family

ID=48521400

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010410564.8A Active CN111643524B (zh) 2013-03-01 2013-04-30 从外周血中产生肿瘤反应性t细胞富集群的方法
CN201380075806.0A Active CN105163745B (zh) 2013-03-01 2013-04-30 从外周血中产生肿瘤反应性t细胞富集群的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010410564.8A Active CN111643524B (zh) 2013-03-01 2013-04-30 从外周血中产生肿瘤反应性t细胞富集群的方法

Country Status (8)

Country Link
US (3) US9844569B2 (enExample)
EP (2) EP3628322A1 (enExample)
JP (4) JP6257655B2 (enExample)
CN (2) CN111643524B (enExample)
AU (4) AU2013379773B2 (enExample)
CA (1) CA2902448C (enExample)
ES (1) ES2771251T3 (enExample)
WO (1) WO2014133568A1 (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105483088B (zh) 2005-10-18 2021-05-28 国家犹太健康中心 条件无限增殖化长期干细胞和制备和使用所述细胞的方法
ES2820873T3 (es) 2008-05-16 2021-04-22 Taiga Biotechnologies Inc Anticuerpos y su procesos de preparación
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
CA3133302A1 (en) 2012-07-20 2014-01-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
CN111643524B (zh) * 2013-03-01 2023-09-05 美国卫生和人力服务部 从外周血中产生肿瘤反应性t细胞富集群的方法
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
ES2980788T3 (es) 2014-04-10 2024-10-03 H Lee Moffitt Cancer Ct & Res Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
ES2924709T3 (es) * 2014-10-02 2022-10-10 Us Health Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
EP3848456A1 (en) 2014-10-02 2021-07-14 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016179006A1 (en) 2015-05-01 2016-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
IL302102A (en) 2015-05-20 2023-06-01 Dana Farber Cancer Inst Inc shared neoantigens
CN104946589A (zh) * 2015-07-07 2015-09-30 英普乐孚生物技术(上海)有限公司 一种肿瘤特异性til细胞的分离培养方法
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
EP3922716A1 (en) * 2016-03-17 2021-12-15 Berkeley Lights, Inc. Selection and cloning of t lymphocytes in a microfluidic device
MA45595A (fr) 2016-07-07 2019-05-15 Iovance Biotherapeutics Inc Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
JP2019532652A (ja) 2016-10-26 2019-11-14 アイオバンス バイオセラピューティクス，インコーポレイテッド 凍結保存腫瘍浸潤リンパ球の再刺激
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
BR112019009925A2 (pt) 2016-11-17 2019-10-08 Iovance Biotherapeutics Inc método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer .
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
EP3610266A4 (en) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary TUMOR SIGNATURE FOR METASTASIS, COMPOSITIONS OF MATERIAL AND THEIR METHODS OF USE
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
PE20251254A1 (es) 2017-05-24 2025-05-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
US11819517B2 (en) 2017-06-05 2023-11-21 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN115028739A (zh) 2017-08-03 2022-09-09 泰加生物工艺学公司 用于治疗黑素瘤的方法和组合物
CN109423478A (zh) * 2017-08-22 2019-03-05 郑州大学第附属医院 一种记忆性t细胞的制备方法
EP3695408A4 (en) 2017-10-02 2021-12-15 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
CN108254557B (zh) * 2017-12-26 2019-05-31 首都医科大学附属北京地坛医院 用cd8阳性的t细胞上pd-1和tigit确定hbv相关原发性肝癌预后的系统
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
BR112020013848A2 (pt) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210130779A1 (en) 2018-04-27 2021-05-06 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US12473532B2 (en) 2018-05-10 2025-11-18 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
ES3036072T3 (en) 2018-11-05 2025-09-12 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
AU2020274117A1 (en) 2019-05-14 2021-12-02 Taiga Biotechnologies, Inc. Compositions and methods for treating T cell exhaustion
CN110452870A (zh) * 2019-05-20 2019-11-15 河南省肿瘤医院 一种肿瘤特异性t细胞的分离培养方法及由其获得的产品
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
TW202206592A (zh) 2020-04-22 2022-02-16 美商艾歐凡斯生物治療公司 用於協調產製供病患特異性免疫治療之細胞的系統和方法
CN111850119B (zh) * 2020-06-04 2022-08-26 吴式琇 定量检测bst1、stab1和tlr4基因表达水平的方法及应用
RU2752973C1 (ru) * 2020-10-12 2021-08-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ определения качественных параметров иммуносупрессивных клеток у онкологических пациентов
CN112266899A (zh) * 2020-10-26 2021-01-26 北京卡替医疗技术有限公司 修饰的免疫细胞及其用途
EP4416292A2 (en) 2021-10-14 2024-08-21 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
EP1263928B1 (en) * 2000-02-11 2007-09-26 Dana-Farber Cancer Institute, Inc. Identification of antigenic peptides by cytotoxic t lymphocytes activated by dendritic cell hybrids
DE10232697A1 (de) 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
CA2497552C (en) * 2002-09-06 2014-05-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US20040250305A1 (en) 2002-09-09 2004-12-09 Latif Zuhair A. Adoptive transfer and uses thereof
US20040224402A1 (en) 2003-05-08 2004-11-11 Xcyte Therapies, Inc. Generation and isolation of antigen-specific T cells
JPWO2007018198A1 (ja) * 2005-08-09 2009-02-19 国立大学法人 熊本大学 Ｈｌａ−ａ２陽性者用ｈｓｐ１０５由来癌拒絶抗原ペプチド及びこれを含む医薬
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
NZ600758A (en) * 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US9416165B2 (en) * 2007-10-26 2016-08-16 The Regents Of The University Of California Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
CA2713462C (en) 2008-01-29 2020-04-14 Fred Hutchinson Cancer Research Center Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity
AU2009210221B2 (en) 2008-01-31 2014-06-26 Bayer Cropscience Aktiengesellschaft The use of alternan as ingredient for certain foodstuffs
WO2010006808A1 (en) * 2008-07-18 2010-01-21 Sentoclone Ab Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer
CN101625361A (zh) 2009-02-26 2010-01-13 中国人民解放军第二军医大学 一种慢性乙型肝炎患者免疫状态的诊断方法
US8741642B2 (en) * 2010-10-22 2014-06-03 Virginia Commonwealth University Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN102935228B (zh) * 2011-08-15 2015-02-18 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的试剂、其用途及方法
JP2014020930A (ja) 2012-07-18 2014-02-03 Kanazawa Univ 膵癌診断及び治療効果予測判定バイオマーカー
CN111643524B (zh) 2013-03-01 2023-09-05 美国卫生和人力服务部 从外周血中产生肿瘤反应性t细胞富集群的方法
CN104371974B (zh) 2014-10-24 2017-03-22 杭州阿诺生物医药科技股份有限公司 一种自体外周血淋巴细胞cik的培养方法
CN105754990A (zh) 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用
CR20200608A (es) 2016-04-21 2021-01-20 Immatics Biotechnologies Gmbh INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551)
CN106177931B (zh) 2016-08-25 2018-02-02 河北浓孚雨生物科技有限公司 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法
CN106957905B (zh) 2016-12-23 2020-12-04 孙涛 一种用于评估肿瘤免疫治疗效果的分子检测方法及引物组合物及试剂盒
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
RU2662916C1 (ru) 2017-06-05 2018-07-31 Общество с ограниченной ответственностью "Альтернативные Инновационные Технологии" Способ терапии метастатического рака с использованием вируса Сендай
EP3647433B1 (en) 2017-06-30 2023-04-12 Osaka University Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood t cells as index
CN108254557B (zh) 2017-12-26 2019-05-31 首都医科大学附属北京地坛医院 用cd8阳性的t细胞上pd-1和tigit确定hbv相关原发性肝癌预后的系统

Also Published As

Publication number Publication date
AU2013379773A1 (en) 2015-09-17
US20160008400A1 (en) 2016-01-14
AU2018204458A1 (en) 2018-07-12
EP2961416B1 (en) 2019-11-13
CN105163745A (zh) 2015-12-16
AU2019284080B2 (en) 2021-02-11
JP6903558B2 (ja) 2021-07-14
AU2018204458B2 (en) 2019-09-26
CN111643524B (zh) 2023-09-05
AU2019284080A1 (en) 2020-01-23
US20200323908A1 (en) 2020-10-15
AU2013379773B2 (en) 2018-04-19
US10716809B2 (en) 2020-07-21
WO2014133568A1 (en) 2014-09-04
US9844569B2 (en) 2017-12-19
ES2771251T3 (es) 2020-07-06
EP2961416A1 (en) 2016-01-06
JP7252383B2 (ja) 2023-04-04
JP7029617B2 (ja) 2022-03-04
CN111643524A (zh) 2020-09-11
US20180133253A1 (en) 2018-05-17
CA2902448C (en) 2023-04-18
EP3628322A1 (en) 2020-04-01
AU2021202640A1 (en) 2021-05-27
CA2902448A1 (en) 2014-09-04
JP2020054371A (ja) 2020-04-09
AU2021202640B2 (en) 2023-04-13
US11679128B2 (en) 2023-06-20
JP2016509840A (ja) 2016-04-04
JP2022058791A (ja) 2022-04-12
JP6257655B2 (ja) 2018-01-10
JP2018082702A (ja) 2018-05-31

Similar Documents

Publication Publication Date Title
CN105163745B (zh) 从外周血中产生肿瘤反应性t细胞富集群的方法
JP7181917B2 (ja) 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法
HK40035292A (en) Methods of producing enriched populations of tumor reactive t cells from peripheral blood
HK40026892A (en) Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer
RU2808817C2 (ru) Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
KR20240170059A (ko) 면역 세포 치료를 위한 종양 반응성이 있는 t 세포 집단을 활성화시켜 증식하는 방법
HK40053468A (en) Methods of producing enriched populations of tumor-reactive t cells from tumor
HK40035292B (zh) 从外周血中产生肿瘤反应性t细胞富集群的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant